Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

IGFBP7 (insulin-like growth factor-binding protein 7) works as a tumor suppressor as well as an oncogene by controlling cell proliferation, cell attachment, apoptosis and angiogenesis. It is also involved in TGFβ (transforming growth factor β) signal pathway. IGFBP7 also interferes with the insulin pathway and is associated with the development of diabetes as well as cardiovascular diseases.

General description

IGFBP7 (insulin-like growth factor-binding protein 7) is from the IGFBP superfamily and is widely expressed in tissues. It is a 30kDa secreted protein and contains 11 cysteines, a heparin binding site, a Kazal-type trypsin inhibitor domain and a carboxyl-terminal immunoglobulin-like type C repeat. IGFBP7 binds weakly to IGFs (insulin like growth factors) and strongly to insulin. It mainly participates in IGF-independent pathways. The IGFBP7 gene is mapped to human chromosome 4q12. Recombinant human IGF-BP7 is a 26.4kDa protein consisting of 257 amino acid residues.

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 6.8.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

MSSSDTCGPC EPASCPPLPP LGCLLGETRD ACGCCPMCAR GEGEPCGGGG AGRGYCAPGM ECVKSRKRRK GKAGAAAGGP GVSGVCVCKS RYPVCGSDGT TYPSGCQLRA ASQRAESRGE KAITQVSKGT CEQGPSIVTP PKDIWNVTGA QVYLSCEVIG IPTPVLIWNK VKRGHYGVQR TELLPGDRDN LAIQTRGGPE KHEVTGWVLV SPLSKEDAGE YECHASNSQG QASASAKITV VDALHEIPVK KGEGAEL